常山药业(300255.SZ)发预亏，预计2025年度归母净亏损1.9亿元至2.85亿元

Group 1 - The company Changshan Pharmaceutical (300255.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of between 190 million to 285 million yuan [1] - The net loss after deducting non-recurring gains and losses is projected to be between 191 million to 286 million yuan [1]